Toleranzia AB signs agreement for the manufacture of a cell bank
27 January - 2016
Toleranzia AB has signed an agreement assigning Biotechpharma UAB to manufacture a so-called “Research Cell Bank”. This consists of E. coli bacteria and constitutes the starting material for producing the tolerogen that the company is developing for the treatment of myasthenia gravis.
In the following step, Biotechpharma UAB will use the cell bank to scale up the production process within the frame of the Eurostars project, which Toleranzia AB and Biotechpharma UAB partake in and which was granted funding in the beginning of 2015.
Charlotte Fribert, COO, comments
It is pleasing that we have now taken the first step towards the establishment of a large-scale production process. The protein that Biotechpharma produces for us will be used to study stability, as well as for formulation, toxicology and safety studies.
For further information about the above-mentioned agreement, please contact:
Charlotte Fribert – COO
Phone: +46 763-19 98 98
E-mail: charlotte.fribert@toleranzia.com
For further information about Toleranzia AB, please contact:
Björn Löwenadler, CEO
Phone: +46 70-631 00 30
E-mail: bjorn.lowenadler@toleranzia.com
About the company
Toleranzia AB (556877-2866) has developed a platform technology for treatment of autoimmune diseases. The company´s main project is directed towards an autoimmune neuromuscular disease, myasthenia gravis, with a significant need for an effective treatment and an extensive market potential, for which Toleranzia has been granted Orphan Drug Designation in both EU and US. The platform technology enables development of therapies that target the root cause of the disease – not just the symptoms, which is the mainstay of current treatment. In addition to myasthenia gravis, the platform technology has been evaluated in three further disease indications – rheumatoid arthritis, multiple sclerosis and type 1 diabetes, where positive treatment effects have been obtained in disease-relevant animal models. Toleranzia was founded by researchers at the University of Gothenburg. The company has operations at the Biotech center in Gothenburg. Further reading at: www.toleranzia.com.